De-Risking Technology Transfer for Gene Therapy Manufacturing
In gene therapy manufacturing, technology transfer is more than moving a process from one facility to another. Technology transfer for gene therapy manufacturing involves transferring scientific understanding, operational experience, and practical knowledge needed to manufacture a product consistently in a new environment, often as part of AAV manufacturing technology transfer or broader CDMO technology transfer gene therapy collaborations. It requires clear scope, defined roles, risk-based planning, and documentation that enables reproducible execution at the receiving site.
A batch record can describe what to do. A successful technology transfer for gene therapy manufacturing must also explain why each step matters, where variability can arise, and how to respond when a process deviates from expectations. This is critical to AAV manufacturing technology transfer, where subtle changes can affect vector quality, and to CDMO technology transfer gene therapy programs that span multiple facilities.
At Andelyn Biosciences, we combine structured knowledge transfer, early risk assessment, cross-functional collaboration, and documented manufacturing readiness. The objective is to establish a process that the receiving site can execute independently and reliably while meeting product quality and regulatory requirements.
What Technology Transfer Must Accomplish
ICH Q10 defines technology transfer as the transfer of product and process knowledge between development and manufacturing, and within or between manufacturing sites, to achieve product realization. That knowledge underpins the manufacturing process, control strategy, process validation approach, and continual improvement. In practice, technology transfer for gene therapy manufacturing addresses what activities will be moved, why each is critical, and how controls will be implemented at the new site.
In practice, tech transfer can take several forms:
- Moving a process between sites within the same organization.
- Scaling a process within an existing organization.
- Transferring a process from a developer to a contract development and manufacturing organization (CDMO).
- Transferring a process to a new organization while also changing manufacturing scale.
Each scenario presents different considerations. Equipment, materials, analytical methods, facility layouts, and operator practices may differ between the sending and receiving sites. These differences require assessment, even when the intended manufacturing process remains the same. For AAV manufacturing technology transfer, this includes vector-specific assays and raw material criticality.
The goal is not merely to reproduce a sequence of manufacturing steps. It is to establish the process understanding and controls needed to achieve the intended product quality at the receiving site, which is why technology transfer is important in gene therapy production: it safeguards comparability, compliance, and reliable supply, especially in CDMO technology transfer gene therapy settings.
Transferring Knowledge, Not Just Documents
A complete tech transfer package includes more than just process parameters and batch records. It should capture:
- Process descriptions and operating requirements.
- Material specifications and equipment needs.
- Analytical methods.
- Critical quality attributes and critical process parameters.
- Historical process performance.
- Previous deviations and known risks.
- Practical knowledge gained during development and manufacturing.
That last category can be particularly important. An operator’s technique, the sequence of actions during a processing step, or the interpretation of an in-process result may not be fully captured in a written procedure. Observation runs and direct discussions between technical teams help make this knowledge explicit. Documentation required for a successful gene therapy technology transfer typically includes transfer plans, protocols, comparability reports, master batch records, SOPs, bills of materials, method transfer/qualification reports, validation plans, change controls, and training records.
Tech transfer is therefore a two-way exchange. The sending site must communicate its process understanding. The receiving site must ask questions, identify gaps, and determine how the process will operate within its facility, equipment, personnel, and quality systems. Manufacturing, MS&T, QA, QC, engineering, supply chain, validation, and program management all contribute.
Four Pillars of Tech Transfer Readiness
1. Equipment and facility readiness
Assess scale, equipment compatibility, process kits, single-use bioreactor interfaces, facility layout, and utilities. Qualify, maintain, and calibrate equipment. When needed, non-GMP engineering runs evaluate performance before GMP execution.
2. Raw material and consumable readiness
Define specifications for raw materials, single-use assemblies, bags, and filters. Assess suitability and equivalency when materials differ. Use a complete bill of materials for supplier qualification, sourcing, inventory planning, and release testing.
3. Product testing and analytical transfer
Prepare QC labs for in-process and release testing. Establish acceptance criteria for method comparability and data review workflows. Analytical readiness should advance alongside manufacturing readiness, a common challenge in transferring gene therapy manufacturing processes.
4. Quality governance and regulatory readiness
Use formal change control, cross-functional gap assessments, and risk assessments to guide master batch records, SOPs, sampling plans, and other controlled documents. QA oversight ensures alignment with current GMP and regulatory expectations.
Turning Process Knowledge into an Executable Manufacturing Process
New product introduction coordinates supply chain planning, analytical transfer, equipment preparation, and documentation in parallel. Key elements include:
- Formal change control: Define activities, assign owners, and establish oversight.
- Tech transfer documentation: Translate sending-site knowledge into receiving-site requirements.
- Gap and risk assessments: Identify impacts on quality, performance, facility fit, testing, materials, and timelines.
- Product release requirements: Align expectations, testing, documentation, and controls.
- Bill of materials: Complete list of raw materials, consumables, and components.
- Master batch records: Controlled instructions, parameters, in-process checks, holds, and documentation.
- Operational readiness: Confirm methods, materials, equipment, and suites are ready.
- Personnel training: Train and qualify staff on procedures, equipment, sampling, and product specifics.
When needed, engineering runs and comparability studies verify execution with site-specific equipment, materials, procedures, and operators. Typical timelines for technology transfer for gene therapy manufacturing range from 3 to 12 months, depending on scope, assay transfers, material lead times, and regulatory needs, and can be longer for complex CDMO technology transfer gene therapy programs.
Andelyn’s Approach to Tech Transfer
Andelyn’s roots at Nationwide Children’s Hospital inform our work as a concept-to-commercial gene therapy CDMO. Our manufacturing, process development, analytical, and MS&T teams contribute complementary expertise. Our experience spans adherent and suspension processes, an in-house AAV platform, and work across AAV, lentiviral, and HSV modalities, supporting robust AAV manufacturing technology transfer.
The Measure of a Successful Transfer
A successful transfer is demonstrated when the receiving site understands the process, has addressed risks, and can reliably manufacture to required quality standards. By treating technology transfer for gene therapy manufacturing as a structured readiness process, teams can identify gaps sooner, prepare more effectively, and build a stronger foundation for clinical and commercial manufacturing across CDMO technology transfer gene therapy networks.
Planning an Upcoming Tech Transfer or Process Scale-Up?
Whether you are scaling an early-phase process, transitioning to GMP manufacturing, or preparing for commercial production, connect with our MS&T team to discuss your program requirements and how we can support your path to the clinic and beyond. Contact Our Tech Transfer Team.
In gene therapy manufacturing, technology transfer is more than moving a process from one facility to another. Technology transfer for gene therapy manufacturing involves transferring scientific understanding, operational experience, and practical knowledge needed to manufacture a product consistently in a new environment, often as part of AAV manufacturing technology transfer or broader CDMO technology transfer gene therapy collaborations. It requires clear scope, defined roles, risk-based planning, and documentation that enables reproducible execution at the receiving site.
A batch record can describe what to do. A successful technology transfer for gene therapy manufacturing must also explain why each step matters, where variability can arise, and how to respond when a process deviates from expectations. This is critical to AAV manufacturing technology transfer, where subtle changes can affect vector quality, and to CDMO technology transfer gene therapy programs that span multiple facilities.
At Andelyn Biosciences, we combine structured knowledge transfer, early risk assessment, cross-functional collaboration, and documented manufacturing readiness. The objective is to establish a process that the receiving site can execute independently and reliably while meeting product quality and regulatory requirements.
What Technology Transfer Must Accomplish
ICH Q10 defines technology transfer as the transfer of product and process knowledge between development and manufacturing, and within or between manufacturing sites, to achieve product realization. That knowledge underpins the manufacturing process, control strategy, process validation approach, and continual improvement. In practice, technology transfer for gene therapy manufacturing addresses what activities will be moved, why each is critical, and how controls will be implemented at the new site.
In practice, tech transfer can take several forms:
- Moving a process between sites within the same organization.
- Scaling a process within an existing organization.
- Transferring a process from a developer to a contract development and manufacturing organization (CDMO).
- Transferring a process to a new organization while also changing manufacturing scale.
Each scenario presents different considerations. Equipment, materials, analytical methods, facility layouts, and operator practices may differ between the sending and receiving sites. These differences require assessment, even when the intended manufacturing process remains the same. For AAV manufacturing technology transfer, this includes vector-specific assays and raw material criticality.
The goal is not merely to reproduce a sequence of manufacturing steps. It is to establish the process understanding and controls needed to achieve the intended product quality at the receiving site, which is why technology transfer is important in gene therapy production: it safeguards comparability, compliance, and reliable supply, especially in CDMO technology transfer gene therapy settings.
Transferring Knowledge, Not Just Documents
A complete tech transfer package includes more than just process parameters and batch records. It should capture:
- Process descriptions and operating requirements.
- Material specifications and equipment needs.
- Analytical methods.
- Critical quality attributes and critical process parameters.
- Historical process performance.
- Previous deviations and known risks.
- Practical knowledge gained during development and manufacturing.
That last category can be particularly important. An operator’s technique, the sequence of actions during a processing step, or the interpretation of an in-process result may not be fully captured in a written procedure. Observation runs and direct discussions between technical teams help make this knowledge explicit. Documentation required for a successful gene therapy technology transfer typically includes transfer plans, protocols, comparability reports, master batch records, SOPs, bills of materials, method transfer/qualification reports, validation plans, change controls, and training records.
Tech transfer is therefore a two-way exchange. The sending site must communicate its process understanding. The receiving site must ask questions, identify gaps, and determine how the process will operate within its facility, equipment, personnel, and quality systems. Manufacturing, MS&T, QA, QC, engineering, supply chain, validation, and program management all contribute.
Four Pillars of Tech Transfer Readiness
1. Equipment and facility readiness
Assess scale, equipment compatibility, process kits, single-use bioreactor interfaces, facility layout, and utilities. Qualify, maintain, and calibrate equipment. When needed, non-GMP engineering runs evaluate performance before GMP execution.
2. Raw material and consumable readiness
Define specifications for raw materials, single-use assemblies, bags, and filters. Assess suitability and equivalency when materials differ. Use a complete bill of materials for supplier qualification, sourcing, inventory planning, and release testing.
3. Product testing and analytical transfer
Prepare QC labs for in-process and release testing. Establish acceptance criteria for method comparability and data review workflows. Analytical readiness should advance alongside manufacturing readiness, a common challenge in transferring gene therapy manufacturing processes.
4. Quality governance and regulatory readiness
Use formal change control, cross-functional gap assessments, and risk assessments to guide master batch records, SOPs, sampling plans, and other controlled documents. QA oversight ensures alignment with current GMP and regulatory expectations.
Turning Process Knowledge into an Executable Manufacturing Process
New product introduction coordinates supply chain planning, analytical transfer, equipment preparation, and documentation in parallel. Key elements include:
- Formal change control: Define activities, assign owners, and establish oversight.
- Tech transfer documentation: Translate sending-site knowledge into receiving-site requirements.
- Gap and risk assessments: Identify impacts on quality, performance, facility fit, testing, materials, and timelines.
- Product release requirements: Align expectations, testing, documentation, and controls.
- Bill of materials: Complete list of raw materials, consumables, and components.
- Master batch records: Controlled instructions, parameters, in-process checks, holds, and documentation.
- Operational readiness: Confirm methods, materials, equipment, and suites are ready.
- Personnel training: Train and qualify staff on procedures, equipment, sampling, and product specifics.
When needed, engineering runs and comparability studies verify execution with site-specific equipment, materials, procedures, and operators. Typical timelines for technology transfer for gene therapy manufacturing range from 3 to 12 months, depending on scope, assay transfers, material lead times, and regulatory needs, and can be longer for complex CDMO technology transfer gene therapy programs.
Andelyn’s Approach to Tech Transfer
Andelyn’s roots at Nationwide Children’s Hospital inform our work as a concept-to-commercial gene therapy CDMO. Our manufacturing, process development, analytical, and MS&T teams contribute complementary expertise. Our experience spans adherent and suspension processes, an in-house AAV platform, and work across AAV, lentiviral, and HSV modalities, supporting robust AAV manufacturing technology transfer.
The Measure of a Successful Transfer
A successful transfer is demonstrated when the receiving site understands the process, has addressed risks, and can reliably manufacture to required quality standards. By treating technology transfer for gene therapy manufacturing as a structured readiness process, teams can identify gaps sooner, prepare more effectively, and build a stronger foundation for clinical and commercial manufacturing across CDMO technology transfer gene therapy networks.
Planning an Upcoming Tech Transfer or Process Scale-Up?
Whether you are scaling an early-phase process, transitioning to GMP manufacturing, or preparing for commercial production, connect with our MS&T team to discuss your program requirements and how we can support your path to the clinic and beyond. Contact Our Tech Transfer Team.
In gene therapy manufacturing, technology transfer is more than moving a process from one facility to another. Technology transfer for gene therapy manufacturing involves transferring scientific understanding, operational experience, and practical knowledge needed to manufacture a product consistently in a new environment, often as part of AAV manufacturing technology transfer or broader CDMO technology transfer gene therapy collaborations. It requires clear scope, defined roles, risk-based planning, and documentation that enables reproducible execution at the receiving site.
A batch record can describe what to do. A successful technology transfer for gene therapy manufacturing must also explain why each step matters, where variability can arise, and how to respond when a process deviates from expectations. This is critical to AAV manufacturing technology transfer, where subtle changes can affect vector quality, and to CDMO technology transfer gene therapy programs that span multiple facilities.
At Andelyn Biosciences, we combine structured knowledge transfer, early risk assessment, cross-functional collaboration, and documented manufacturing readiness. The objective is to establish a process that the receiving site can execute independently and reliably while meeting product quality and regulatory requirements.
What Technology Transfer Must Accomplish
ICH Q10 defines technology transfer as the transfer of product and process knowledge between development and manufacturing, and within or between manufacturing sites, to achieve product realization. That knowledge underpins the manufacturing process, control strategy, process validation approach, and continual improvement. In practice, technology transfer for gene therapy manufacturing addresses what activities will be moved, why each is critical, and how controls will be implemented at the new site.
In practice, tech transfer can take several forms:
- Moving a process between sites within the same organization.
- Scaling a process within an existing organization.
- Transferring a process from a developer to a contract development and manufacturing organization (CDMO).
- Transferring a process to a new organization while also changing manufacturing scale.
Each scenario presents different considerations. Equipment, materials, analytical methods, facility layouts, and operator practices may differ between the sending and receiving sites. These differences require assessment, even when the intended manufacturing process remains the same. For AAV manufacturing technology transfer, this includes vector-specific assays and raw material criticality.
The goal is not merely to reproduce a sequence of manufacturing steps. It is to establish the process understanding and controls needed to achieve the intended product quality at the receiving site, which is why technology transfer is important in gene therapy production: it safeguards comparability, compliance, and reliable supply, especially in CDMO technology transfer gene therapy settings.
Transferring Knowledge, Not Just Documents
A complete tech transfer package includes more than just process parameters and batch records. It should capture:
- Process descriptions and operating requirements.
- Material specifications and equipment needs.
- Analytical methods.
- Critical quality attributes and critical process parameters.
- Historical process performance.
- Previous deviations and known risks.
- Practical knowledge gained during development and manufacturing.
That last category can be particularly important. An operator’s technique, the sequence of actions during a processing step, or the interpretation of an in-process result may not be fully captured in a written procedure. Observation runs and direct discussions between technical teams help make this knowledge explicit. Documentation required for a successful gene therapy technology transfer typically includes transfer plans, protocols, comparability reports, master batch records, SOPs, bills of materials, method transfer/qualification reports, validation plans, change controls, and training records.
Tech transfer is therefore a two-way exchange. The sending site must communicate its process understanding. The receiving site must ask questions, identify gaps, and determine how the process will operate within its facility, equipment, personnel, and quality systems. Manufacturing, MS&T, QA, QC, engineering, supply chain, validation, and program management all contribute.
Four Pillars of Tech Transfer Readiness
1. Equipment and facility readiness
Assess scale, equipment compatibility, process kits, single-use bioreactor interfaces, facility layout, and utilities. Qualify, maintain, and calibrate equipment. When needed, non-GMP engineering runs evaluate performance before GMP execution.
2. Raw material and consumable readiness
Define specifications for raw materials, single-use assemblies, bags, and filters. Assess suitability and equivalency when materials differ. Use a complete bill of materials for supplier qualification, sourcing, inventory planning, and release testing.
3. Product testing and analytical transfer
Prepare QC labs for in-process and release testing. Establish acceptance criteria for method comparability and data review workflows. Analytical readiness should advance alongside manufacturing readiness, a common challenge in transferring gene therapy manufacturing processes.
4. Quality governance and regulatory readiness
Use formal change control, cross-functional gap assessments, and risk assessments to guide master batch records, SOPs, sampling plans, and other controlled documents. QA oversight ensures alignment with current GMP and regulatory expectations.
Turning Process Knowledge into an Executable Manufacturing Process
New product introduction coordinates supply chain planning, analytical transfer, equipment preparation, and documentation in parallel. Key elements include:
- Formal change control: Define activities, assign owners, and establish oversight.
- Tech transfer documentation: Translate sending-site knowledge into receiving-site requirements.
- Gap and risk assessments: Identify impacts on quality, performance, facility fit, testing, materials, and timelines.
- Product release requirements: Align expectations, testing, documentation, and controls.
- Bill of materials: Complete list of raw materials, consumables, and components.
- Master batch records: Controlled instructions, parameters, in-process checks, holds, and documentation.
- Operational readiness: Confirm methods, materials, equipment, and suites are ready.
- Personnel training: Train and qualify staff on procedures, equipment, sampling, and product specifics.
When needed, engineering runs and comparability studies verify execution with site-specific equipment, materials, procedures, and operators. Typical timelines for technology transfer for gene therapy manufacturing range from 3 to 12 months, depending on scope, assay transfers, material lead times, and regulatory needs, and can be longer for complex CDMO technology transfer gene therapy programs.
Andelyn’s Approach to Tech Transfer
Andelyn’s roots at Nationwide Children’s Hospital inform our work as a concept-to-commercial gene therapy CDMO. Our manufacturing, process development, analytical, and MS&T teams contribute complementary expertise. Our experience spans adherent and suspension processes, an in-house AAV platform, and work across AAV, lentiviral, and HSV modalities, supporting robust AAV manufacturing technology transfer.
The Measure of a Successful Transfer
A successful transfer is demonstrated when the receiving site understands the process, has addressed risks, and can reliably manufacture to required quality standards. By treating technology transfer for gene therapy manufacturing as a structured readiness process, teams can identify gaps sooner, prepare more effectively, and build a stronger foundation for clinical and commercial manufacturing across CDMO technology transfer gene therapy networks.
Planning an Upcoming Tech Transfer or Process Scale-Up?
Whether you are scaling an early-phase process, transitioning to GMP manufacturing, or preparing for commercial production, connect with our MS&T team to discuss your program requirements and how we can support your path to the clinic and beyond. Contact Our Tech Transfer Team.